Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
12 mai 2021 16h05 HE
|
Salarius Pharmaceuticals, Inc.
Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat Conference Call and Live Audio Webcast Scheduled for...
Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results
05 mai 2021 07h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting
29 avr. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting
19 avr. 2021 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results
18 mars 2021 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 18, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results
11 mars 2021 16h15 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option
08 mars 2021 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock
04 mars 2021 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Announces Proposed Public Offering of Common Stock
03 mars 2021 16h05 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas
24 févr. 2021 07h00 HE
|
Salarius Pharmaceuticals, Inc.
Relapsed and refractory Ewing sarcoma patients to receive seclidemstat in combination with chemotherapy agents as second- and third-line therapy; Protocol amendment expands and improves access to...